EcoDrugPlus

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSBBBG00000019107
Gene Symbol: MAP3K12
3 Cross references
254 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSBBBG00000020778
Gene Symbol: MAP3K13
3 Cross references
201 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 5

Ensembl ID : ENSBBBG00000025426
Gene Symbol: MAP3K5
3 Cross references
209 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSBBBG00000012373
Gene Symbol: MAP3K8
3 Cross references
199 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSBBBG00000006680
Gene Symbol: MAP3K9
3 Cross references
195 Possible Orthologues:

Motilin Receptor

Ensembl ID : ENSBBBG00000014952
Gene Symbol: MLNR
3 Cross references
163 Possible Orthologues:

Myeloperoxidase

Ensembl ID : ENSBBBG00000002163
Gene Symbol: MPO
3 Cross references
182 Possible Orthologues:

Natriuretic Peptide Receptor 1

Ensembl ID : ENSBBBG00000002615
Gene Symbol: NPR1
3 Cross references
186 Possible Orthologues:

Natriuretic Peptide Receptor 2

Ensembl ID : ENSBBBG00000016918
Gene Symbol: NPR2
3 Cross references
260 Possible Orthologues:

Natriuretic Peptide Receptor 3

Ensembl ID : ENSBBBG00000022379
Gene Symbol: NPR3
3 Cross references
210 Possible Orthologues:

Neuropeptide Y Receptor Y2

Ensembl ID : ENSBBBG00000014909
Gene Symbol: NPY2R
3 Cross references
248 Possible Orthologues:

Neuropeptide Y Receptor Y5

Ensembl ID : ENSBBBG00000014527
Gene Symbol: NPY5R
3 Cross references
137 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).